StockIQ.techImmunityBio, Inc. (IBRX) Stock Analysis
Free AI-powered analysis and research for ImmunityBio, Inc. stock
Sector: Healthcare
Full IBRX report
ImmunityBio, Inc. (IBRX) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze IBRX Now →📰 Latest Update
SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus
Mon, November 2, 2026 at 6:11 AM UTC 3 min read
ImmunityBio (IBRX) ended October down 12%, underperforming the SPDR S&P Biotech ETF, which fell 1.1%. The decline comes amid earnings updates from Merck and AstraZeneca, highlighting competition in cancer treatments and potential buyout opportunities. While IBRX has seen significant year-to-date gains of 319%, recent sentiment on Stocktwits has been bearish, contrasting with the more optimistic outlook for other biotech stocks like Sellas Life Sciences and Iovance Biotherapeutics.